Status:
COMPLETED
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
Lead Sponsor:
Pfizer
Conditions:
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Eligibility:
All Genders
40-80 years
Phase:
PHASE2
Brief Summary
To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)
Eligibility Criteria
Inclusion
- Post-bronchodilator FEV1/FVC ratio \<0.7 and a post-bronchodilator FEV1 of 50-80%.
- Diagnosis of moderate COPD for a minimum of 6 months.
- Stable disease for at least 1 month prior to screening
Exclusion
- More than 2 exacerbations of COPD requiring treatment with oral steroids in the preceding year or hospitalisation for the treatment of COPD within 3 months of screening or more than twice during the preceding year.
- History of a lower respiratory tract infection or significant disease instability during the month preceding screening or during the time between screening and randomisation.
Key Trial Info
Start Date :
March 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
405 Patients enrolled
Trial Details
Trial ID
NCT00808288
Start Date
March 1 2010
End Date
December 1 2010
Last Update
February 6 2019
Active Locations (75)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Fairhope, Alabama, United States, 36532
2
Pfizer Investigational Site
San Diego, California, United States, 92120
3
Pfizer Investigational Site
Spring Valley, California, United States, 91978
4
Pfizer Investigational Site
Wheat Ridge, Colorado, United States, 80033